ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

Jacques Fellay; Alexander J. Thompson; Dongliang Ge; Curtis E. Gumbs; Thomas J. Urban; Kevin V. Shianna; Latasha D. Little; Ping Qiu; Arthur H. Bertelsen; Mark Watson; Amelia Warner; Andrew J. Muir; Clifford Brass; Janice Albrecht; Mark Sulkowski; John G. McHutchison; David B. Goldstein

doi:10.1038/nature08825

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

Jacques Fellay, Alexander J. Thompson, Dongliang Ge, Curtis E. Gumbs, Thomas J. Urban, Kevin V. Shianna, Latasha D. Little, Ping Qiu, Arthur H. Bertelsen, Mark Watson, Amelia Warner, Andrew J. Muir, Clifford Brass, Janice Albrecht, Mark Sulkowski, John G. McHutchison, David B. Goldstein

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.

Original language	English (US)
Pages (from-to)	405-408
Number of pages	4
Journal	Nature
Volume	464
Issue number	7287
DOIs	https://doi.org/10.1038/nature08825
State	Published - Mar 18 2010

ASJC Scopus subject areas

General

Access to Document

10.1038/nature08825

Fingerprint Dive into the research topics of 'ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C'. Together they form a unique fingerprint.

Cite this

Fellay, J., Thompson, A. J., Ge, D., Gumbs, C. E., Urban, T. J., Shianna, K. V., Little, L. D., Qiu, P., Bertelsen, A. H., Watson, M., Warner, A., Muir, A. J., Brass, C., Albrecht, J., Sulkowski, M., McHutchison, J. G., & Goldstein, D. B. (2010). ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature, 464(7287), 405-408. https://doi.org/10.1038/nature08825

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. / Fellay, Jacques; Thompson, Alexander J.; Ge, Dongliang; Gumbs, Curtis E.; Urban, Thomas J.; Shianna, Kevin V.; Little, Latasha D.; Qiu, Ping; Bertelsen, Arthur H.; Watson, Mark; Warner, Amelia; Muir, Andrew J.; Brass, Clifford; Albrecht, Janice; Sulkowski, Mark; McHutchison, John G.; Goldstein, David B.

In: Nature, Vol. 464, No. 7287, 18.03.2010, p. 405-408.

Research output: Contribution to journal › Article › peer-review

Fellay, J, Thompson, AJ, Ge, D, Gumbs, CE, Urban, TJ, Shianna, KV, Little, LD, Qiu, P, Bertelsen, AH, Watson, M, Warner, A, Muir, AJ, Brass, C, Albrecht, J, Sulkowski, M, McHutchison, JG & Goldstein, DB 2010, 'ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C', Nature, vol. 464, no. 7287, pp. 405-408. https://doi.org/10.1038/nature08825

Fellay, Jacques ; Thompson, Alexander J. ; Ge, Dongliang ; Gumbs, Curtis E. ; Urban, Thomas J. ; Shianna, Kevin V. ; Little, Latasha D. ; Qiu, Ping ; Bertelsen, Arthur H. ; Watson, Mark ; Warner, Amelia ; Muir, Andrew J. ; Brass, Clifford ; Albrecht, Janice ; Sulkowski, Mark ; McHutchison, John G. ; Goldstein, David B. / ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. In: Nature. 2010 ; Vol. 464, No. 7287. pp. 405-408.

@article{4deab5ee89504875868b50e1880b6f56,

title = "ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C",

abstract = "Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.",

author = "Jacques Fellay and Thompson, {Alexander J.} and Dongliang Ge and Gumbs, {Curtis E.} and Urban, {Thomas J.} and Shianna, {Kevin V.} and Little, {Latasha D.} and Ping Qiu and Bertelsen, {Arthur H.} and Mark Watson and Amelia Warner and Muir, {Andrew J.} and Clifford Brass and Janice Albrecht and Mark Sulkowski and McHutchison, {John G.} and Goldstein, {David B.}",

year = "2010",

month = mar,

day = "18",

doi = "10.1038/nature08825",

language = "English (US)",

volume = "464",

pages = "405--408",

journal = "Nature",

issn = "0028-0836",

publisher = "Nature Publishing Group",

number = "7287",

}

TY - JOUR

T1 - ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

AU - Fellay, Jacques

AU - Thompson, Alexander J.

AU - Ge, Dongliang

AU - Gumbs, Curtis E.

AU - Urban, Thomas J.

AU - Shianna, Kevin V.

AU - Little, Latasha D.

AU - Qiu, Ping

AU - Bertelsen, Arthur H.

AU - Watson, Mark

AU - Warner, Amelia

AU - Muir, Andrew J.

AU - Brass, Clifford

AU - Albrecht, Janice

AU - Sulkowski, Mark

AU - McHutchison, John G.

AU - Goldstein, David B.

PY - 2010/3/18

Y1 - 2010/3/18

N2 - Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.

AB - Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.

UR - http://www.scopus.com/inward/record.url?scp=77949773445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949773445&partnerID=8YFLogxK

U2 - 10.1038/nature08825

DO - 10.1038/nature08825

M3 - Article

C2 - 20173735

AN - SCOPUS:77949773445

VL - 464

SP - 405

EP - 408

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7287

ER -